Novavax claims that their Covid-19 vaccination is 90% effective
Novavax, a US pharmaceutical firm, said Monday that their Covid-19 vaccine had a 90.4 percent overall effectiveness against the coronavirus.
According to the firm, its two-dose vaccination provided 100 percent protection against moderate and severe illness in a trial that comprised 29,960 individuals across 119 locations in the United States.
The vaccine’s effectiveness against certain coronavirus types, which accounted for 82 percent of the cases, was 93.2 percent, according to the study.
In a statement, Gregory M. Glenn, M.D., president of Novavax Research and Development, stated, “These results demonstrate persistent, high levels of effectiveness and confirm the ability of the vaccine to prevent Covid-19 despite continuous genetic development of the virus.”
The vaccine will be submitted for regulatory approval in the third quarter of this year, according to the firm.
By the end of the third quarter, it expects to have reached a production capacity of 100 million doses per month, and 150 million doses per month by the fourth quarter of 2021.
Novavax joins Pfizer-BioNTech, Moderna, and Johnson & Johnson as American pharmaceutical companies that offer vaccinations to the US public.
As of early Sunday, more than 374 million pills had been delivered in the United States, with more than 309 million having been given.
According to the US Centers for Disease Control and Prevention, 143.9 million individuals, or 43.4 percent of the population, have gotten two doses thus far.
According to Johns Hopkins University, more than 33.4 million cases have been reported in the United States since the outbreak began, with almost 600,000 fatalities.
More than 3.8 million people have died as a result of the outbreak, which has affected 176 million people worldwide.
PHOTO: Courtesy of Anadolu